PHAXIAM Therapeutics S.A. Stock price Euronext Paris

Equities

PHXM

FR0011471135

Biotechnology & Medical Research

Market Closed - Euronext Paris 12:20:58 2024-03-28 pm EDT 5-day change 1st Jan Change
2.98 EUR -0.50% Intraday chart for PHAXIAM Therapeutics S.A. +2.23% -35.22%
Sales 2023 - Sales 2024 * - Capitalization 18.19M 19.65M
Net income 2023 -23M -24.84M Net income 2024 * -18M -19.44M EV / Sales 2023 -
Net Debt 2023 * 3.3M 3.56M Net Debt 2024 * 1.7M 1.84M EV / Sales 2024 * -
P/E ratio 2023 *
-0.7 x
P/E ratio 2024 *
-2.14 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 92.13%
More Fundamentals * Assessed data
Dynamic Chart
1 week+0.68%
Current month-1.81%
1 month-1.97%
3 months-33.78%
6 months-37.85%
Current year-35.22%
More quotes
1 week
2.84
Extreme 2.835
3.00
1 month
2.82
Extreme 2.82
3.06
3 years
2.60
Extreme 2.6
75.80
5 years
2.60
Extreme 2.6
114.60
10 years
2.60
Extreme 2.6
402.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 23-06-22
Director of Finance/CFO 57 23-06-22
Chief Tech/Sci/R&D Officer - 23-06-22
Members of the board TitleAgeSince
Director/Board Member 63 23-06-22
Director/Board Member 59 23-06-22
Director/Board Member 62 23-06-22
More insiders
Date Price Change Volume
24-03-28 2.98 -0.50% 5 425
24-03-27 2.995 +3.28% 10,753
24-03-26 2.9 0.00% 1,202
24-03-25 2.9 -1.69% 6,257
24-03-22 2.95 -0.34% 4,277

Real-time Euronext Paris, March 28, 2024 at 12:20 pm EDT

More quotes
Following the merger with PHERECYDES in June 2023, ERYTECH Pharma S.A. has changed its corporate name to PHAXIAM Therapeutics S.A. The new group is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.995 EUR
Average target price
9.6 EUR
Spread / Average Target
+220.53%
Consensus
  1. Stock
  2. Equities
  3. Stock PHAXIAM Therapeutics S.A.
  4. Stock PHAXIAM Therapeutics S.A. - Euronext Paris